Insight, China's Pharmaceutical Industry

Company Drug

Eli Lilly’s Retatrutide Delivers 2.0% A1C Reduction and 36.6 Lbs Weight Loss in Phase 3 Diabetes Trial – Triple‑Agonist Shows Best‑in‑Class Efficacy

Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 TRANSCEND‑T2D‑1...

Company Drug

Pfizer Reports Positive TALAPRO-3 Results – TALZENNA/XTANDI Combo Hits Primary Endpoint in HRR-Mutated Prostate Cancer

Fineline Cube Mar 20, 2026

Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 TALAPRO-3 study, demonstrating...

Others

Luzhu Biotechnology Reports 2025 Results – LZ901 Shingles Vaccine Nears Commercialization with Shingrix‑Beating Data

Fineline Cube Mar 20, 2026

Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901...

Company Deals

Samsung Bioepis Expands Sandoz Partnership – Global Deal for Five Biosimilars Including Entyvio Copycat SB36

Fineline Cube Mar 20, 2026

Samsung Bioepis Co., Ltd. has expanded its strategic partnership with Sandoz AG (SWX: SDZ), entering...

Company Drug

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Fineline Cube Mar 19, 2026

Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that ABSK061 received Orphan Drug Designation (ODD) from...

Company Drug

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Fineline Cube Mar 19, 2026

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced the initiation of a Phase III clinical...

Company Drug

Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma

Fineline Cube Mar 19, 2026

Konruns Pharmaceutical Co., Ltd. (SHA: 603590) received National Medical Products Administration (NMPA) approval to initiate...

Company Drug

InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis

Fineline Cube Mar 19, 2026

InventisBio (Shanghai) Co., Ltd. (SHA: 688382) announced FDA clearance to initiate a Phase II clinical...

Company Drug

Kintor Pharma’s KX-826 Hits Phase III Endpoint in Hair Loss – Androgen Receptor Antagonist Tincture Shows 15.33 Hairs/cm² Growth vs. Placebo

Fineline Cube Mar 19, 2026

Suzhou Kintor Pharmaceuticals, Inc. (HKG: 9939) announced that its pivotal Phase III clinical study for...

Medical Device

Super Vision Technology Wins NMPA Approval for Ocular Neurostimulator – First-in-Class Implantable Device Treats Congenital Nystagmus

Fineline Cube Mar 19, 2026

Super Vision Technology, Inc. announced National Medical Products Administration (NMPA) approval for its implantable ocular...

Company Deals Medical Device

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities

Fineline Cube Mar 19, 2026

GE HealthCare (NASDAQ: GEHC) announced completion of the acquisition of Intelerad, a leading medical imaging...

Company Deals

Leveragen Partners with Daiichi Sankyo – In Vivo Antibody Discovery Collaboration Targets Advanced Biologics

Fineline Cube Mar 19, 2026

Leveragen, a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, announced a...

Company Drug

J&J’s Icotyde Wins FDA Approval – First Oral IL-23 Receptor Antagonist Targets Moderate-to-Severe Plaque Psoriasis

Fineline Cube Mar 19, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced FDA marketing approval for Icotyde (icotrokinra), an interleukin-23...

Company Drug

Sanofi’s Venglustat Wins FDA Breakthrough Therapy Designation – Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms

Fineline Cube Mar 19, 2026

Sanofi (NASDAQ: SNY) announced that venglustat received Breakthrough Therapy Designation (BTD) from the U.S. Food...

Company Deals

Medbanks Acquires Jianyi Tech for RMB 360 Million – Insurance-Tech Deal Strengthens Corporate Health Security Platform

Fineline Cube Mar 19, 2026

Sipai Health Technology Co., Ltd. (HKG: 0314), operating as Medbanks, announced the acquisition of 100%...

Company Drug

TransThera Sciences Doses First Patient in Phase II Tinengotinib Combination Study – Multi-Kinase Inhibitor Plus Fulvestrant Targets HR+/HER2- Breast Cancer

Fineline Cube Mar 19, 2026

TransThera Sciences (Nanjing), Inc. (HKG: 2617) announced first patient dosing in a Phase II clinical...

Company Deals

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Fineline Cube Mar 19, 2026

Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751...

Company Deals

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

Fineline Cube Mar 19, 2026

Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ:...

Policy / Regulatory

FDA Releases Draft Guidance on NAMs – Accelerating Shift from Animal Testing to Human‑Relevant Drug Safety Assessment

Fineline Cube Mar 19, 2026

The US Food and Drug Administration (FDA) has advanced its “Roadmap to Reducing Animal Testing...

Company Drug

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Fineline Cube Mar 18, 2026

Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China’s...

Insight, China's Pharmaceutical Industry

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

Allist Pharmaceuticals Secures Exclusive Greater China License for ArriVent’s Bispecific ADC AST12608/ARR-002

Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea

CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab

Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease

Eli Lilly’s Retatrutide Delivers 2.0% A1C Reduction and 36.6 Lbs Weight Loss in Phase 3 Diabetes Trial – Triple‑Agonist Shows Best‑in‑Class Efficacy

Pfizer Reports Positive TALAPRO-3 Results – TALZENNA/XTANDI Combo Hits Primary Endpoint in HRR-Mutated Prostate Cancer

Luzhu Biotechnology Reports 2025 Results – LZ901 Shingles Vaccine Nears Commercialization with Shingrix‑Beating Data

Samsung Bioepis Expands Sandoz Partnership – Global Deal for Five Biosimilars Including Entyvio Copycat SB36

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma

InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis

Kintor Pharma’s KX-826 Hits Phase III Endpoint in Hair Loss – Androgen Receptor Antagonist Tincture Shows 15.33 Hairs/cm² Growth vs. Placebo

Super Vision Technology Wins NMPA Approval for Ocular Neurostimulator – First-in-Class Implantable Device Treats Congenital Nystagmus

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities

Leveragen Partners with Daiichi Sankyo – In Vivo Antibody Discovery Collaboration Targets Advanced Biologics

J&J’s Icotyde Wins FDA Approval – First Oral IL-23 Receptor Antagonist Targets Moderate-to-Severe Plaque Psoriasis

Sanofi’s Venglustat Wins FDA Breakthrough Therapy Designation – Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms

Medbanks Acquires Jianyi Tech for RMB 360 Million – Insurance-Tech Deal Strengthens Corporate Health Security Platform

TransThera Sciences Doses First Patient in Phase II Tinengotinib Combination Study – Multi-Kinase Inhibitor Plus Fulvestrant Targets HR+/HER2- Breast Cancer

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

FDA Releases Draft Guidance on NAMs – Accelerating Shift from Animal Testing to Human‑Relevant Drug Safety Assessment

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

You Missed

AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab

Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform